Lercanidipine Viatris (Lercanidipine Hydrochloride)

Lercanidipine blocks L‑type calcium channels in vascular smooth‑muscle cells, preventing calcium entry that is necessary for muscle contraction. This inhibition leads to vasodilation of peripheral arteries, decreasing systemic vascular resistance and consequently lowering blood pressure.

The appropriate dose of Lercanidipine is determined by the prescribing clinician based on the individual’s blood‑pressure response, age, renal and hepatic function, and concomitant medications. The prescriber will select a starting dose and may adjust it to achieve optimal control.

Safety data for Lercanidipine in pregnancy and lactation are limited. It is generally classified as contraindicated or to be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lercanidipine Viatris. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lercanidipine, a dihydropyridine calcium‑channel blocker, primarily causes arterial vasodilation, whereas agents such as ACE inhibitors reduce angiotensin‑II mediated vasoconstriction and beta‑blockers lower heart rate and contractility. Lercanidipine often provides a smoother blood‑pressure reduction with a lower incidence of reflex tachycardia compared with some older calcium‑channel blockers.

Store Lercanidipine tablets at room temperature, below 25 °C, in the original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability throughout its shelf life.

Lercanidipine is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events, although rare, include severe hypotension, angioedema, myocardial infarction, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience sudden dizziness, swelling of the face or throat, chest pain, or signs of liver dysfunction such as jaundice.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors without appropriate medical supervision.